Report cover image

Global Enzalutamide Drugs Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 207 Pages
SKU # APRC20278931

Description

Summary

According to APO Research, the global Enzalutamide Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Enzalutamide Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Enzalutamide Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Enzalutamide Drugs market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Enzalutamide Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Enzalutamide Drugs market include Yichang Humanwell Pharmaceutical, Shenyang Hongqi Pharmaceutical, PuraCap Pharmaceuticals, Qilu Pharmaceutical, Kelun Pharmaceutical, Jiangsu Hansoh Pharmaceutical, Zydus, Sun Pharma and Pfizer, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Enzalutamide Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Enzalutamide Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Enzalutamide Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Enzalutamide Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Enzalutamide Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Enzalutamide Drugs sales, projected growth trends, production technology, application and end-user industry.


Enzalutamide Drugs Segment by Company


Yichang Humanwell Pharmaceutical

Shenyang Hongqi Pharmaceutical

PuraCap Pharmaceuticals

Qilu Pharmaceutical

Kelun Pharmaceutical

Jiangsu Hansoh Pharmaceutical

Zydus

Sun Pharma

Pfizer

Intas Pharmaceuticals

Glenmark Pharma

Beacon pharma

BDR Pharma

Astellas Pharma

Arechar Healthcare

Aprazer Healthcare Pharma

Abbott Laboratories

Enzalutamide Drugs Segment by Type


Tablets

Capsules

Enzalutamide Drugs Segment by Application


Hospital and Clinic

Retail Pharmacies

Other

Enzalutamide Drugs Segment by Region


North America


United States

Canada

Mexico

Europe


Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific


China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America


Brazil

Argentina

Chile

Middle East & Africa


Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Enzalutamide Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Enzalutamide Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Enzalutamide Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze Enzalutamide Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Enzalutamide Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Enzalutamide Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Enzalutamide Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Enzalutamide Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Enzalutamide Drugs industry.
Chapter 3: Detailed analysis of Enzalutamide Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Enzalutamide Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Enzalutamide Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

207 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Enzalutamide Drugs Sales Value (2020-2031)
1.2.2 Global Enzalutamide Drugs Sales Volume (2020-2031)
1.2.3 Global Enzalutamide Drugs Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Enzalutamide Drugs Market Dynamics
2.1 Enzalutamide Drugs Industry Trends
2.2 Enzalutamide Drugs Industry Drivers
2.3 Enzalutamide Drugs Industry Opportunities and Challenges
2.4 Enzalutamide Drugs Industry Restraints
3 Enzalutamide Drugs Market by Company
3.1 Global Enzalutamide Drugs Company Revenue Ranking in 2024
3.2 Global Enzalutamide Drugs Revenue by Company (2020-2025)
3.3 Global Enzalutamide Drugs Sales Volume by Company (2020-2025)
3.4 Global Enzalutamide Drugs Average Price by Company (2020-2025)
3.5 Global Enzalutamide Drugs Company Ranking (2023-2025)
3.6 Global Enzalutamide Drugs Company Manufacturing Base and Headquarters
3.7 Global Enzalutamide Drugs Company Product Type and Application
3.8 Global Enzalutamide Drugs Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Enzalutamide Drugs Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Enzalutamide Drugs Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Enzalutamide Drugs Market by Type
4.1 Enzalutamide Drugs Type Introduction
4.1.1 Tablets
4.1.2 Capsules
4.2 Global Enzalutamide Drugs Sales Volume by Type
4.2.1 Global Enzalutamide Drugs Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Enzalutamide Drugs Sales Volume by Type (2020-2031)
4.2.3 Global Enzalutamide Drugs Sales Volume Share by Type (2020-2031)
4.3 Global Enzalutamide Drugs Sales Value by Type
4.3.1 Global Enzalutamide Drugs Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Enzalutamide Drugs Sales Value by Type (2020-2031)
4.3.3 Global Enzalutamide Drugs Sales Value Share by Type (2020-2031)
5 Enzalutamide Drugs Market by Application
5.1 Enzalutamide Drugs Application Introduction
5.1.1 Hospital and Clinic
5.1.2 Retail Pharmacies
5.1.3 Other
5.2 Global Enzalutamide Drugs Sales Volume by Application
5.2.1 Global Enzalutamide Drugs Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Enzalutamide Drugs Sales Volume by Application (2020-2031)
5.2.3 Global Enzalutamide Drugs Sales Volume Share by Application (2020-2031)
5.3 Global Enzalutamide Drugs Sales Value by Application
5.3.1 Global Enzalutamide Drugs Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Enzalutamide Drugs Sales Value by Application (2020-2031)
5.3.3 Global Enzalutamide Drugs Sales Value Share by Application (2020-2031)
6 Enzalutamide Drugs Regional Sales and Value Analysis
6.1 Global Enzalutamide Drugs Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Enzalutamide Drugs Sales by Region (2020-2031)
6.2.1 Global Enzalutamide Drugs Sales by Region: 2020-2025
6.2.2 Global Enzalutamide Drugs Sales by Region (2026-2031)
6.3 Global Enzalutamide Drugs Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Enzalutamide Drugs Sales Value by Region (2020-2031)
6.4.1 Global Enzalutamide Drugs Sales Value by Region: 2020-2025
6.4.2 Global Enzalutamide Drugs Sales Value by Region (2026-2031)
6.5 Global Enzalutamide Drugs Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Enzalutamide Drugs Sales Value (2020-2031)
6.6.2 North America Enzalutamide Drugs Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Enzalutamide Drugs Sales Value (2020-2031)
6.7.2 Europe Enzalutamide Drugs Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Enzalutamide Drugs Sales Value (2020-2031)
6.8.2 Asia-Pacific Enzalutamide Drugs Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Enzalutamide Drugs Sales Value (2020-2031)
6.9.2 South America Enzalutamide Drugs Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Enzalutamide Drugs Sales Value (2020-2031)
6.10.2 Middle East & Africa Enzalutamide Drugs Sales Value Share by Country, 2024 VS 2031
7 Enzalutamide Drugs Country-level Sales and Value Analysis
7.1 Global Enzalutamide Drugs Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Enzalutamide Drugs Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Enzalutamide Drugs Sales by Country (2020-2031)
7.3.1 Global Enzalutamide Drugs Sales by Country (2020-2025)
7.3.2 Global Enzalutamide Drugs Sales by Country (2026-2031)
7.4 Global Enzalutamide Drugs Sales Value by Country (2020-2031)
7.4.1 Global Enzalutamide Drugs Sales Value by Country (2020-2025)
7.4.2 Global Enzalutamide Drugs Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.5.2 USA Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.6.2 Canada Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.8.2 Germany Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.9.2 France Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.9.3 France Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.11.2 Italy Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.12.2 Spain Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.13.2 Russia Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.16.2 China Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.16.3 China Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.17.2 Japan Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.19.2 India Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.19.3 India Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.20.2 Australia Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.24.2 Chile Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.26.2 Peru Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.28.2 Israel Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.29.2 UAE Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.31.2 Iran Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Enzalutamide Drugs Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Enzalutamide Drugs Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Enzalutamide Drugs Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Yichang Humanwell Pharmaceutical
8.1.1 Yichang Humanwell Pharmaceutical Comapny Information
8.1.2 Yichang Humanwell Pharmaceutical Business Overview
8.1.3 Yichang Humanwell Pharmaceutical Enzalutamide Drugs Sales, Value and Gross Margin (2020-2025)
8.1.4 Yichang Humanwell Pharmaceutical Enzalutamide Drugs Product Portfolio
8.1.5 Yichang Humanwell Pharmaceutical Recent Developments
8.2 Shenyang Hongqi Pharmaceutical
8.2.1 Shenyang Hongqi Pharmaceutical Comapny Information
8.2.2 Shenyang Hongqi Pharmaceutical Business Overview
8.2.3 Shenyang Hongqi Pharmaceutical Enzalutamide Drugs Sales, Value and Gross Margin (2020-2025)
8.2.4 Shenyang Hongqi Pharmaceutical Enzalutamide Drugs Product Portfolio
8.2.5 Shenyang Hongqi Pharmaceutical Recent Developments
8.3 PuraCap Pharmaceuticals
8.3.1 PuraCap Pharmaceuticals Comapny Information
8.3.2 PuraCap Pharmaceuticals Business Overview
8.3.3 PuraCap Pharmaceuticals Enzalutamide Drugs Sales, Value and Gross Margin (2020-2025)
8.3.4 PuraCap Pharmaceuticals Enzalutamide Drugs Product Portfolio
8.3.5 PuraCap Pharmaceuticals Recent Developments
8.4 Qilu Pharmaceutical
8.4.1 Qilu Pharmaceutical Comapny Information
8.4.2 Qilu Pharmaceutical Business Overview
8.4.3 Qilu Pharmaceutical Enzalutamide Drugs Sales, Value and Gross Margin (2020-2025)
8.4.4 Qilu Pharmaceutical Enzalutamide Drugs Product Portfolio
8.4.5 Qilu Pharmaceutical Recent Developments
8.5 Kelun Pharmaceutical
8.5.1 Kelun Pharmaceutical Comapny Information
8.5.2 Kelun Pharmaceutical Business Overview
8.5.3 Kelun Pharmaceutical Enzalutamide Drugs Sales, Value and Gross Margin (2020-2025)
8.5.4 Kelun Pharmaceutical Enzalutamide Drugs Product Portfolio
8.5.5 Kelun Pharmaceutical Recent Developments
8.6 Jiangsu Hansoh Pharmaceutical
8.6.1 Jiangsu Hansoh Pharmaceutical Comapny Information
8.6.2 Jiangsu Hansoh Pharmaceutical Business Overview
8.6.3 Jiangsu Hansoh Pharmaceutical Enzalutamide Drugs Sales, Value and Gross Margin (2020-2025)
8.6.4 Jiangsu Hansoh Pharmaceutical Enzalutamide Drugs Product Portfolio
8.6.5 Jiangsu Hansoh Pharmaceutical Recent Developments
8.7 Zydus
8.7.1 Zydus Comapny Information
8.7.2 Zydus Business Overview
8.7.3 Zydus Enzalutamide Drugs Sales, Value and Gross Margin (2020-2025)
8.7.4 Zydus Enzalutamide Drugs Product Portfolio
8.7.5 Zydus Recent Developments
8.8 Sun Pharma
8.8.1 Sun Pharma Comapny Information
8.8.2 Sun Pharma Business Overview
8.8.3 Sun Pharma Enzalutamide Drugs Sales, Value and Gross Margin (2020-2025)
8.8.4 Sun Pharma Enzalutamide Drugs Product Portfolio
8.8.5 Sun Pharma Recent Developments
8.9 Pfizer
8.9.1 Pfizer Comapny Information
8.9.2 Pfizer Business Overview
8.9.3 Pfizer Enzalutamide Drugs Sales, Value and Gross Margin (2020-2025)
8.9.4 Pfizer Enzalutamide Drugs Product Portfolio
8.9.5 Pfizer Recent Developments
8.10 Intas Pharmaceuticals
8.10.1 Intas Pharmaceuticals Comapny Information
8.10.2 Intas Pharmaceuticals Business Overview
8.10.3 Intas Pharmaceuticals Enzalutamide Drugs Sales, Value and Gross Margin (2020-2025)
8.10.4 Intas Pharmaceuticals Enzalutamide Drugs Product Portfolio
8.10.5 Intas Pharmaceuticals Recent Developments
8.11 Glenmark Pharma
8.11.1 Glenmark Pharma Comapny Information
8.11.2 Glenmark Pharma Business Overview
8.11.3 Glenmark Pharma Enzalutamide Drugs Sales, Value and Gross Margin (2020-2025)
8.11.4 Glenmark Pharma Enzalutamide Drugs Product Portfolio
8.11.5 Glenmark Pharma Recent Developments
8.12 Beacon pharma
8.12.1 Beacon pharma Comapny Information
8.12.2 Beacon pharma Business Overview
8.12.3 Beacon pharma Enzalutamide Drugs Sales, Value and Gross Margin (2020-2025)
8.12.4 Beacon pharma Enzalutamide Drugs Product Portfolio
8.12.5 Beacon pharma Recent Developments
8.13 BDR Pharma
8.13.1 BDR Pharma Comapny Information
8.13.2 BDR Pharma Business Overview
8.13.3 BDR Pharma Enzalutamide Drugs Sales, Value and Gross Margin (2020-2025)
8.13.4 BDR Pharma Enzalutamide Drugs Product Portfolio
8.13.5 BDR Pharma Recent Developments
8.14 Astellas Pharma
8.14.1 Astellas Pharma Comapny Information
8.14.2 Astellas Pharma Business Overview
8.14.3 Astellas Pharma Enzalutamide Drugs Sales, Value and Gross Margin (2020-2025)
8.14.4 Astellas Pharma Enzalutamide Drugs Product Portfolio
8.14.5 Astellas Pharma Recent Developments
8.15 Arechar Healthcare
8.15.1 Arechar Healthcare Comapny Information
8.15.2 Arechar Healthcare Business Overview
8.15.3 Arechar Healthcare Enzalutamide Drugs Sales, Value and Gross Margin (2020-2025)
8.15.4 Arechar Healthcare Enzalutamide Drugs Product Portfolio
8.15.5 Arechar Healthcare Recent Developments
8.16 Aprazer Healthcare Pharma
8.16.1 Aprazer Healthcare Pharma Comapny Information
8.16.2 Aprazer Healthcare Pharma Business Overview
8.16.3 Aprazer Healthcare Pharma Enzalutamide Drugs Sales, Value and Gross Margin (2020-2025)
8.16.4 Aprazer Healthcare Pharma Enzalutamide Drugs Product Portfolio
8.16.5 Aprazer Healthcare Pharma Recent Developments
8.17 Abbott Laboratories
8.17.1 Abbott Laboratories Comapny Information
8.17.2 Abbott Laboratories Business Overview
8.17.3 Abbott Laboratories Enzalutamide Drugs Sales, Value and Gross Margin (2020-2025)
8.17.4 Abbott Laboratories Enzalutamide Drugs Product Portfolio
8.17.5 Abbott Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Enzalutamide Drugs Value Chain Analysis
9.1.1 Enzalutamide Drugs Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Enzalutamide Drugs Sales Mode & Process
9.2 Enzalutamide Drugs Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Enzalutamide Drugs Distributors
9.2.3 Enzalutamide Drugs Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.